FY2024 Earnings Estimate for Danaher Co. (NYSE:DHR) Issued By William Blair

Danaher Co. (NYSE:DHR - Free Report) - Equities research analysts at William Blair increased their FY2024 EPS estimates for shares of Danaher in a report released on Wednesday, April 24th. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings of $7.67 per share for the year, up from their previous estimate of $7.61. The consensus estimate for Danaher's current full-year earnings is $7.64 per share.

Several other research firms also recently commented on DHR. Citigroup boosted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a "buy" rating in a research note on Wednesday. Bank of America boosted their price target on shares of Danaher from $258.00 to $270.00 and gave the stock a "neutral" rating in a research note on Wednesday. Royal Bank of Canada boosted their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 31st. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 31st. Finally, Robert W. Baird boosted their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an "outperform" rating in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $270.00.

Danaher Trading Up 0.3 %

Danaher stock traded up $0.65 during trading on Friday, hitting $246.45. The company had a trading volume of 2,710,445 shares, compared to its average volume of 2,785,746. The company's 50 day simple moving average is $248.94 and its 200-day simple moving average is $230.88. The stock has a market cap of $182.54 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 4.19 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter last year, the firm earned $2.36 EPS. The firm's revenue for the quarter was down 2.6% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Cape Investment Advisory Inc. purchased a new position in Danaher in the fourth quarter valued at about $25,000. Tsfg LLC increased its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate's stock valued at $25,000 after buying an additional 88 shares in the last quarter. BKM Wealth Management LLC purchased a new position in Danaher in the fourth quarter valued at about $27,000. Wetzel Investment Advisors Inc. purchased a new position in Danaher in the fourth quarter valued at about $29,000. Finally, OFI Invest Asset Management purchased a new position in Danaher in the third quarter valued at about $30,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Teri List sold 3,289 shares of the business's stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Joakim Weidemanis sold 22,433 shares of the business's stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at $22,644,589.52. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of the business's stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 106,565 shares of company stock valued at $26,641,364. Insiders own 11.10% of the company's stock.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is a boost from Danaher's previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher's dividend payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.